ATACAS wins ACTA Clinical Trial of the Year Award
ATACAS (Aspirin and Tranexamic Acid for Coronary Artery Surgery) has been awarded the prestigious Clinical Trial of the Year Award at the Clinical Trials 2017 National Tribute and Awards Ceremony in Sydney this month. Federal Minister for Health, Greg Hunt, presented the award on Friday May 19th.
The annual award ceremony celebrates the Australian teams behind large multinational investigator initiated clinical trials that influence clinical practice and patient care in the Australian healthcare system.
ATACAS, an NHMRC funded trial supported by ANZCA, Monash University and NIHR, found that taking Aspirin before open heart surgery protects against heart attack and stroke, and that tranexamic acid does not increase thrombosis after open heart surgery.
Research Path’s web-based Clinical Trial Management System was used for this trial, including randomisation and telephone-based voice recognition software. Technical Director Adam Meehan was also the Data Manager for duration of the trial that launched in May 2006 and ran for 10 years, recruiting over 4,000 patients at over 30 sites around the world.
We would like to say well done to the ATACAS Team, in particular Principal Investigator Dr Paul Myles and Trial Coordinator Sophie Wallace for their incredible work. It has been a pleasure to have been involved.
We are certain this won’t be the last time that a trial we are involved with receives this award.
Research Path is proud to be an Affiliate Member of the Australian Clinical Trials Alliance. To find out more about ACTA and the benefits of membership, visit: http://www.clinicaltrialsalliance.org.au/about-acta/membership/.
If you are a member of ANZCA and want to know more about joining the Clinical Trials Network visit http://www.anzca.edu.au/ctn.
Further reading:
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery (New England Jounrnal of Medicine)
ATACAS Named 2017 Trial of the Year (ACTA Announcment)